201-963-1

Applied Filters:

Keyword:'201-963-1'

Showing 1-1 of 1 result for "201-963-1" within Papers

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Rachel S Kerr et al.

The Lancet. Oncology, 17(11), 1543-1557 (2016-09-24)

Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. For the open-label, randomised, controlled QUASAR 2 trial, which was

Page 1 of 1